- Home
- ABOS vs INBX Comparison
ABOS vs INBX Comparison
Compare ABOS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABOS | INBX |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.7M | 999.7M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ABOS | INBX |
|---|---|---|
| Price | $2.88 | $82.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $8.00 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 511.6K | 220.4K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $0.95 | $10.90 |
| 52 Week High | $3.60 | $94.57 |
Technical Indicators
Market Signals| Indicator | ABOS | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 61.43 |
| Support Level | $2.19 | $71.31 |
| Resistance Level | $3.05 | $85.97 |
| Average True Range (ATR) | 0.17 | 5.43 |
| MACD | 0.04 | 2.37 |
| Stochastic Oscillator | 85.62 | 76.09 |
Price Performance
Historical ComparisonAbout ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.